Scottsdale, United States
PathogenDx, a biotechnology firm based in the United States, is revolutionizing the molecular testing landscape. With its slogan, "Setting the Standard in Molecular Testing," the company stands out for its innovative technology designed to detect pathogens swiftly and precisely.
Founded in 2015, PathogenDx has developed the patented Dynamic Dimensional Detection (D3 Array™) technology. This cutting-edge solution allows for the simultaneous detection and identification of up to 50 pathogens within a single well test, producing results in under a single work shift. The technology is equipment agnostic, enabling seamless integration, and leverages automated, cloud-based analytics to serve the clinical, food, and agricultural industries.
In its most recent financing round, PathogenDx secured a $7.50M Series B investment on 30 September 2019, attracting funding from notable investors including HALLEY Venture Partners, Salveo Capital, and Altitude Investment Management among others. The company continues to be a key player in enhancing health and safety standards across multiple sectors.
OlfaGuard - food safety by nano technology